Boehringer Ingelheim reported Phase 3 success for survodutide, a dual-acting obesity shot designed to stimulate GLP-1 and glucagon signaling. In the Synchronize-1 trial, Boehringer said treatment groups achieved up to 17% weight loss among those staying on through evaluation, versus about 3% with placebo, with 5% weight loss achieved by up to 85% of treated patients. The company also highlighted data suggesting reductions in weight while preserving muscle, an issue that has become central as competitors pursue similar cardiometabolic outcomes. At the same time, AstraZeneca is exiting parts of its pipeline after disappointing efficacy, underscoring how quickly obesity and adjacent metabolic portfolios can face portfolio reshaping if late-stage programs fail. Overall, the new Phase 3 signal adds another candidate to the obesity market where payers, trial endpoints, and durability expectations are increasingly decisive.